Nasdaq Edit News Today

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price […]

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month […]

Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) – Analysts at Zacks Research increased their Q1 2024 EPS estimates for shares of Editas Medicine in a research note issued on Thursday, February 15th. Zacks Research analyst A. Chakraborty now expects that the company will earn ($0.71) per share for the quarter, up from their prior estimate […]

Raymond James & Associates lifted its stake in Editas Medicine, Inc. (NASDAQ:EDIT – Free Report) by 5.8% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 274,303 shares of the company’s stock after acquiring an additional 14,994 shares during the period. Raymond James & Associates’ holdings in Editas Medicine were worth $2,140,000 as […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) saw a significant decrease in short interest in December. As of December 31st, there was short interest totalling 12,790,000 shares, a decrease of 14.6% from the December 15th total of 14,970,000 shares. Based on an average daily volume of 1,840,000 shares, the days-to-cover ratio is presently 7.0 […]

StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a research report sent to investors on Tuesday. Other research analysts have also issued research reports about the company. Citigroup raised Editas Medicine from a neutral rating to a buy rating and set a $11.00 target […]

StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a report released on Tuesday. Several other research analysts also recently weighed in on the company. Citigroup upgraded Editas Medicine from a neutral rating to a buy rating and set a $11.00 target price on the […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has received a consensus recommendation of “Hold” from the thirteen research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have issued a buy recommendation on the company. The average […]

Shares of Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) have earned an average recommendation of “Hold” from the thirteen research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have assigned a buy recommendation […]

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) gapped up before the market opened on Wednesday after Truist Financial raised their price target on the stock from $15.00 to $20.00. The stock had previously closed at $9.84, but opened at $10.38. Truist Financial currently has a buy rating on the stock. Editas Medicine shares last […]